Taboo populations, foods, and restrictions of Gefitinib in Laos
Gefitinib, as an EGFR-TKI inhibitor, is contraindicated in patients with specific genotypes, pregnancy, and organ dysfunction, while also paying attention to drug interactions and dietary restrictions. The following provides a detailed explanation from three aspects: taboo populations, taboo foods, and medication restrictions.
1. Taboo population
(1) Genetic testing negative: EGFR mutation negative non-small cell lung cancer patients are contraindicated (objective response rate<10%).
(2) Pregnancy period: Animal studies have shown embryotoxicity, and pregnant women should use reliable contraceptive measures until 2 weeks after discontinuing medication.
(3) Severe liver injury: Not recommended for Child Pugh C patients (blood drug concentration can increase by 50%).
2. Forbidden foods
(1) Grapefruit products: Inhibiting CYP3A4 metabolism increases blood drug concentration by 2.5 times.
(2) High fat diet: Taking it with a standard meal can reduce AUC by 47%, and it should be taken on an empty stomach or 2 hours after a meal.
(3) St. John's wort: induces CYP3A4 to reduce drug exposure by 65%.
3. Medication restrictions
(1) Interstitial lung disease: It is contraindicated for patients with a medical history, and monitoring for newly developed respiratory distress is necessary during treatment.
(2) Liver function monitoring: ALT should be tested before treatment and monthly. If the ULN is greater than 5 times, the medication should be permanently discontinued.
(3) Ophthalmic examination: If symptoms of keratitis appear, medication should be immediately suspended.
Disclaimer：《Taboo populations, foods, and restrictions of Gefitinib in Laos》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！